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Abstract
Background: Crohns disease (CD) and ulcerative colitis (UC) are characterized by a dysregulated inflammatory 
response to normal constituents of the intestinal flora in the genetically predisposed host. Heme oxygenase-1 (HO-1/
HMOX1) is a powerful anti-inflammatory and anti-oxidant enzyme, whereas the pro-inflammatory interleukin 1β (IL-1β/
IL1B) and anti-inflammatory interleukin 10 (IL-10/IL10) are key modulators for the initiation and maintenance of 
inflammation. We investigated whether single nucleotide polymorphisms (SNPs) in the IL-1β, IL-10, and HO-1 genes, 
together with smoking, were associated with risk of CD and UC.
Methods: Allele frequencies of the IL-1β T-31C (rs1143627), and IL-10 rs3024505, G-1082A (rs1800896), C-819T 
(rs1800871), and C-592A (rs1800872) and HO-1 A-413T (rs2071746) SNPs were assessed using a case-control design in a 
Danish cohort of 336 CD and 498 UC patients and 779 healthy controls. Odds ratio (OR) and 95% confidence interval 
(95% CI) were estimated by logistic regression models.
Results: Carriers of rs3024505, a marker polymorphism flanking the IL-10 gene, were at increased risk of CD (OR = 1.40, 
95% CI: 1.06-1.85, P = 0.02) and UC (OR = 1.43, 95% CI: 1.12-1.82, P = 0.004) and, furthermore, with risk of a diagnosis of 
CD and UC at young age (OR = 1.47, 95% CI: 1.10-1.96) and OR = 1.35, 95% CI: 1.04-1.76), respectively). No association 
was found between the IL-1β, IL-10 G-1082A, C-819T, C-592A, and HO-1 gene polymorphisms and CD or UC. No 
consistent interactions between smoking status and CD or UC genotypes were demonstrated.
Conclusions: The rs3024505 marker polymorphism flanking the IL-10 gene was significantly associated with risk of UC 
and CD, whereas no association was found between IL-1β or HO-1 gene polymorphisms and risk of CD and UC in this 
Danish study, suggesting that IL-10, but not IL-1β or HO-1, has a role in IBD etiology in this population.
Background
The chronic inflammatory bowel diseases (IBD), ulcer-
ative colitis (UC) and Crohn's disease (CD), are complex
diseases caused by an interplay between genetic and envi-
ronmental factors [1].
The recent years have brought much progress regard-
ing the genetics in IBD and the number of confirmed IBD
associated loci and genes have risen dramatically [2-7].
Yet, still, only part of the genetic contribution to disease
risk may be explained by the identified genes [8,9].
Northern European populations, including the Danish,
generally have low frequencies of the CD risk-associated
variants of CARD15 [3,10], and it is therefore of interest
to search for more genetic determinants in these popula-
tions. Less progress has been achieved in the identifica-
tion of environmental risk factors and gene-
environmental interactions. Differences in environmental
exposures and genetic heterogeneity between ethnic
groups may have complicated the search for genetic and
gene-environmental determinants.
The emerging picture of IBD pathogenesis is focused
on the sequential occurrence of pivotal events leading to
the initiation and subsequent perpetuation of inflamma-
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Page 2 of 10tion [11,12]. First, the initial interaction between luminal
constituents and intestinal epithelial cells leads to activa-
tion of the innate immune system [11]. The recognition
of highly conserved pathogen structures such as lipopoly-
saccharide (LPS), the main constituent of Gram-negative
bacteria, by Toll-like receptors and other pattern recogni-
tion receptors on the epithelial and other immunologi-
cally active cells in the intestine, initiates the release of
various cytokines and enzymes, including interleukins
(IL) and heme oxygenase-1 [13,14]. Second, the inflam-
mation will eventually become chronic due to defective
regulation of the immune response. Therefore, polymor-
phisms in genes encoding cytokines and other molecules
involved in the innate immune system, may affect the
course of the inflammatory cascade and thereby the risk
of developing IBD.
Activation of the pro-inflammatory IL-1β leads to pro-
duction of prostaglandin E2 (PGE2) and nitric oxide (NO)
via the induction of cyclo-oxygenase 2 (COX-2) and
inducible nitric oxide synthase (iNOS) among others [15].
IL-1β knock-out mice have no spontaneous abnormali-
ties, however, on challenge with LPS, a less pronounced
acute phase response is observed, suggesting that IL-1β is
required for an adequate immune response [15]. In both
CD and UC patients, high levels of IL-1β are found in the
intestinal mucosa [16] and stimulation by IL-1β leads to a
more pronounced inflammatory response in CD immune
cells compared to cells from healthy controls [17]. The
variant alleles of two IL-1β promoter polymorphisms, IL-
1β T-31C and IL-1β C-511T, have been found to be in
almost complete linkage disequilibrium [18], and the
haplotypes encompassing the IL-1β T-31C variant con-
ferred higher transcription of IL-1β compared to the wild
type haplotype [18]. The role of IL-1β polymorphisms in
IBD has been explored in several studies [19-24]. These
studies did not find any association with IL-1β, however,
the studies were rather small.
IL-10 is an anti-inflammatory cytokine, which leads to
dampening of the activated immune system. IL-10 knock-
out mice develop colitis if they are not kept in germ-free
environment [25], and the administration of IL-10 ame-
liorates the inflammation in animal and in vitro models
[26]. In patients, an impaired IL-10 production has been
fund in severe cases of CD and UC [27,28]. Recently, a
strong association between the marker rs3024505 imme-
diately downstream of the IL-10 gene and adult UC was
found in a genome-wide association study [29]. This
study also found a modest association between this
marker and CD risk [29]. However, no association was
found for rs3024493, a linked polymorphism located in
an intron in the IL-10 gene, in a case-control study of pae-
diatric onset CD [30]. The IL-10 promoter is polymor-
phic and genetic variation may account for different
levels of cytokine production [31]. The IL-10 promotor
polymorphisms G-1082A, C-819T, and C-592A have
been most extensively studied. They are in tight linkage
disequilibrium [32] and the haplotype encompassing
these three polymorphisms is associated with low IL-10
protein production in lymphocytes in vitro [32] and low
of levels of circulating IL-10 protein in Kenyan children
[33] probably because the A allele of the IL-10 promoter
polymorphism C-592A leads to the formation of a bind-
ing site for the ETS family of transcription factors [34].
Studies on the IL-10 promoter polymorphisms and IBD
susceptibility have been inconsistent [22,29-31,35-40].
Heme oxygenase-1 (HO-1) is involved in the degrada-
tion of heme, thereby reducing oxidative stress and pro-
tecting against acute and chronic inflammation [41].
Animal models of IBD have confirmed the anti-inflam-
matory effect of HO-1 [42]. Hence, blockade of HO-1
activity results in exacerbation of experimental colitis
whereas increased HO-1 pathway activity ameliorates
experimental murine colitis [43-45]. Carbon monoxide
(CO) is one of the main metabolite of the HO-1 pathway
and CO administration has been shown to ameliorate
chronic colitis in IL-10 deficient mice [42,46]. In UC
patients, HO-1 expression and protein levels have been
reported to be increased in inflamed colon compared to
normal mucosa from patients with UC [47]. Studies using
luciferase reporter assays of a functional promoter poly-
morphism, HO-1 A-413T, indicated that the A allele pro-
moter had significantly higher activity than the T allele
promoter [48]. The AA genotype of this polymorphism
has been associated with a reduced incidence of ischemic
heart disease [48]. Another promoter polymorphism, the
HO-1 (GT)N dinucleotide repeat polymorphism, was not
associated with risk of inflammatory bowel disease [49].
Interestingly, smoking affects the risk of IBD differen-
tially, increasing the risk of CD and reducing the risk of
UC [50]. The mechanisms by which smoking affects risk
of IBD is not clear and as tobacco smoke contains more
than 3000 chemicals, several different mechanisms may
be involved. Nicotine has been reported to modulate the
immune balance in a Th1-dominant direction [51] in
accordance with the beneficial effect of smoking on UC.
Moreover, smoking increases the production of certain
pro-inflammatory cytokines, but, on the other hand,
smoking is a source of carbon monoxide (CO). Thus,
another possible mechanisms may involve interactions
between smoking and IL-1β, IL-10 and HO-1 activity in
relation to intestinal inflammation [46].
In this study we wanted to assess the role of polymor-
phisms in IL-1β, IL-10, and HO-1 together with smoking
in relation to risk of developing IBD in a Danish case-
control study of 336 CD, 498 UC and 779 healthy con-
trols, respectively.
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Patients and controls
Patients with CD (n = 373) or UC (n = 541), and healthy
controls (n = 796) were included. All information was
available for 336 CD cases, 498 UC cases and 779 healthy
controls. Diagnosis of CD or UC was based on clinical,
radiological, endoscopic and histological examinations
[52]. Infectious and other cases of inflammatory bowel
diseases were excluded. IBD diagnoses were classified on
basis of disease localization according to the Montreal
classification; L1, L2, and L3 signifies ileal, colonic, and
ileocolonic localisation in CD and E1, E2, and E3 signifies
the extent of colon involvement in UC; proctitis (inflam-
mation limited to rectum), left side (inflammation distal
to the left flexure), and extensive colon (inflammation
proximal to the left flexure) [53]. Patients were recruited
from Viborg, Aalborg and Herning Regional Hospitals
from January 2004 to March 2005. Healthy blood donors
were recruited from Viborg Hospital. Subjects under the
age of 18 and with ethnicity other than Caucasian were
excluded from the study. Phenotypic data on age at diag-
nosis of disease, localisation, family disposition for IBD,
and medical and surgical treatment of disease was col-
lected. Information on smoking habits at the time of diag-
nosis (patients) and smoking habits at study entry
(donors) was collected.
Genotyping
DNA was extracted from EDTA-stabilized peripheral
blood samples from all patients and healthy controls by
using either a PureGene (Gentra Systems, Minneapolis,
MN, USA) or Wizard Genomic (Promega, Madison, WI,
USA) DNA purification kit, according to the manufactur-
ers' recommendations.
SNPs were chosen from literature studies. IL-1β T-31C
(rs1143627), and IL-10 C-592T (rs1800872) were geno-
typed as previously described [54] Rs3024505, IL-10 G-
1082A (rs1800896), C-819T (rs1800871) [29] were geno-
typed using the pre-developed allelic discrimination
assays C_15983681 20, C_1747360_10 and
C_1747362_10 (Applied Biosystems). The genotyping
reaction was performed in a final volume of 6 μl consist-
ing of 3 μl Universal PCR Master Mix, 0.075 μl 40 ×
assay-on-demand mix, 1.925 μl H2O, and 1 μl genomic
DNA. HO-1 A-413T (rs2071746 was determined using
the pre-developed allelic discrimination assay
C_15869717_10 (Applied Biosystems). Genotyping was
performed by TaqMan real-time PCR on an ABI7900HT
(Applied Biosystems), using Allelic Discrimination.
Twenty ng of DNA was genotyped in 5 μl containing 1 ×
Mastermix (Applied Biosystems, Nærum, Denmark), 100
nM probes, and 900 nM primers or as recommended by
the manufacturer for predesigned assays.. Controls of
known genotypes were included in each run, and
repeated genotyping of a random 10% subset yielded
100% identical genotypes. Laboratory personnel were
blinded to the case/control status of the study group [55].
Statistical analyses
We used logistic regression to analyse the relationship
between the six polymorphisms and disease. The statisti-
cal analyses included only subjects where all information
was available. Age was entered linear in the model after
checking for linearity using a linear spline [56]. Subgroup
analyses were done for the polymorphisms in relation to
location of the disease (CD: L1, L2, L3, UC: E1, E2, E3),
and age at diagnosis (above or not above 40 years of age)
for the cases. The GENMOD procedure in SAS release
9.1 (SAS Institute, Inc., Cary, North Carolina, USA) was
used for the statistical analyses.
Power analyses
We used Genetic Power Calculator for Case - control for
discrete traits [57] for power analyses. This study has
more than 80% power to detect a dominant effect with an
OR of 1.5 in either CD or in UC or 1.4 if CD and UC were
combined.
Ethical Considerations
All subjects received written and oral information and
gave written informed consent. The study was conducted
in accordance with the Declaration of Helsinki and
approved by the local Scientific Ethical Committees at
Viborg and Aalborg County (VN 2003/5).
Results
Characteristics of the Danish IBD patients and controls
are shown in Table 1. A total of 834 Danish patients and
779 controls were included. 51% of the CD patients were
current smokers at the time of diagnosis, whereas only
17% of the UC patients were current smokers. The geno-
type distributions among the controls did not deviate
from Hardy-Weinberg equilibrium. The variant allele fre-
quencies for IL-1β T-31C, IL-10 rs3024505, G-1082A, C-
819T, C-592A and HO-1 A-413T were 0.35, 0.18, 0.45,
0.21, 0.21, and 0.42, respectively, in the control group.
Associations between polymorphisms and disease
Carriers of the variant allele of rs3024505 flanking the IL-
10 gene were at increased risk of both CD and UC.
Homozygous variant allele carriers were at 2.48-fold (95%
CI: 1.27-4.84) increased risk of CD and heterozygous car-
riers were at 1.31-fold (95% CI: 0.98-1.75) increased risk
of CD after adjusting for age, gender and smoking status
(Table 2). Homozygous variant allele carriers were at
2.31-fold (95% CI: 1.27-4.20) increased risk of UC and
heterozygous carriers were at 1.34-fold (95% CI: 1.04-
1.73) increased risk of UC after adjusting for age, gender
and smoking status (Table 3). After correction for multi-
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Page 4 of 10ple testing the associations were borderline statistically
significant. Minor allele frequencies of IL-10 gene poly-
morphisms in selected studies are shown in Table 4.
No association was found between the IL-1β, IL-10 G-
1082A, C-819T, C-592A,, and HO-1 polymorphisms and
risk of CD or UC (Table 2 and 3). The three IL-10 pro-
moter polymorphisms were found to be in almost com-
plete linkage as previously described for Caucasians [32].
Therefore, no haplotype analyses were performed.
No significant difference in the genotype distribution
between CD and UC was found (data not shown). When
combining UC and CD data to increase the statistical
power there were still no associations between the IL-1β,
the three IL-10 promoter polymorphisms, and HO-1 gene
polymorphisms and risk of IBD (results not shown).
Subgroup analyses showed that variant allele carriers of
rs3024505 were at 1.47-fold (95% CI: 1.10-1.96) and 1.35-
fold (95% CI: 1.04-1.76) higher risk of a diagnosis of CD
Table 1: The basic descriptions of the Danish study subjects1.
Crohns Disease Ulcerative Colitis Controls
(n = 336) (n = 498) (n = 779)
Gender: n (%)
male 131 (39) 241 (48) 397 (51)
female 205 (61) 257 (52) 382 (49)
Age:
Median (5%-95%) 43 (23-77) 49 (24-76) 43 (23-60)
Age at diagnosis:
Median (5%-95%) 30 (15-65) 35 (17-68)
Smoking habits: n(%)
Smokers 170 (51) 85 (17) 204 (26)
Never smokers 120 (36) 231 (46) 391 (50)
Former smokers 46 (14) 182 (37) 184 (24)
Location UC2:
Proctitis (E1) 211 (42)
Left side (E2) 183 (37)
Extensive (E3) 94 (19)
Data not available 10 (2)
Location CD2: n (%)
Colonic (L2) 75 (22)
Ileal (L1) 155 (46)
Ileocolonic (L3) 93 (28)
Data not available 13 (4)
Medication: n (%)
Advanced3 142 (42) 104 (21)
No advanced 
medication4
189 (56) 390 (78)
Data not available 5 (1) 4 (1)
Operation: n (%)
Yes 153 (46) 15 (3)
No 176 (52) 473 (95)
Data not available 7 (2) 10 (2)
1The analyses included subjects where all information was available,
2The location of CD and UC in accordance with the Montreal classification are shown.
3azathioprin, 6-mercaptopyrine, Tumor Necrosis Factor-inhibitors, or methrotrexate,
45-aminosalicylic acid, prednisolone
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Table 2: Genotypes in Danish patients with Crohns Disease1.
Ncase Ncontrol OR (95%CI)2 OR (95%CI)3 OR (95%CI)4 P-value5
IL1 β C-31T 
(rs1143627)
TT 165 342 1.00 - 1.00 - 1.00 -
CT 139 342 0.84 (0.64-0.10) 0.85 (0.65-1.12) 0.86 (0.65-1.14) 0.29
CC 32 95 0.70 (0.45-1.09) 0.71 (0.45-1.10) 0.69 (0.44-1.09) 0.11
CT and CC 171 437 0.81 (0.63-1.05) 0.82 (0.63-1.07) 0.82 (0.63-1.07) 0.15
IL-10 C-592A 
(rs1800872)
CC 214 483 1.00 - 1.00 - 1.00 -
AC 114 261 0.99 (0.75-1.29) 0.98 (0.75-1.30) 1.01 (0.76-1.34) 0.97
AA 8 35 0.52 (0.24-1.13) 0.53 (0.24-1.16) 0.54 (0.24-1.21) 0.13
AC and AA 122 296 0.93 (0.71-1.21) 0.93 (0.71-1.22) 0.95 (0.72-1.25) 0.72
IL-10 C-819T 
(rs1800871)
CC 216 483 1.00 - 1.00 - 1.00 -
CT 111 259 0.96 (0.73-1.26) 0.95 (0.72-1.25) 0.97 (0.73-1.29) 0.83
TT 9 37 0.54 (0.26-1.15) 0.55 (0.26-1.18) 0.56 (0.26-1.22) 0.14
CT and TT 120 296 0.91 (0.69-1.18) 0.90 (0.69-1.18) 0.92 (0.70-1.21) 0.55
IL-10 G-1082A 
(rs1800896)
GG 109 238 1.00 - 1.00 - 1.00 -
AG 171 374 1.00 (0.75-1.33) 0.99 (0.74-1.33) 0.97 (0.72-1.32) 0.87
AA 56 167 0.73 (0.50-1.07) 0.75 (0.51-1.10) 0.78 (0.53-1.16) 0.23
AG and AA 227 541 0.92 (0.70-1.21) 0.92 (0.69-1.21) 0.92 (0.69-1.22) 0.56
(rs3024505)
CC 203 522 1.00 - 1.00 - 1.00 -
CT 114 235 1.25 (0.95-1.64) 1.27 (0.96-1.68) 1.31 (0.98-1.75) 0.07
TT 19 22 2.22 (1.18-4.19) 2.60 (1.36-4.96) 2.48 (1.27-4.84) 0.01
CT and TT 133 779 1.33 (1.02-1.73) 1.37 (1.05-1.80) 1.40 (1.06-1.85) 0.02
HO-1 A-413T 
(rs2071746)
AA 110 267 1.00 - 1.00 - 1.00 -
AT 165 373 1.07 (0.81-1.43) 1.06 (0.79-1.42) 1.05 (0.78-1.42) 0.75
TT 61 139 1.07 (0.73-1.55) 1.11 (0.76-1.62) 1.04 (0.70-1.53) 0.86
AT and TT 226 512 1.07 (0.82-1.41) 1.08 (0.82-1.42) 1.05 (0.79-1.39) 0.75
1OR = Odds Ratio, 95%CI = 95% confidence interval,
2 Crude,
3 Adjusted for age and gender,
4 Adjusted for age, gender and smoking status.
5P for the fully adjusted estimate
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Table 3: Genotypes in Danish patients with ulcerative colitis1.
Ncase Ncontrol OR (95%CI)2 OR (95%CI)3 OR (95%CI)4 P-value5
IL1 β C-31T 
(rs1143627)
TT 204 342 1.00 - 1.00 - 1.00 -
CT 238 342 1.17 (0.92-1.48) 1.15 (0.90-1.47) 1.15 (0.89-1.47) 0.28
CC 56 95 0.99 (0.68-1.43) 0.99 (0.68-1.46) 1.02 (0.69-1.49) 0.94
CT and CC 294 437 1.13 (0.90-1.42) 1.11 (0.88-1.41) 1.12 (0.88-1.42) 0.35
IL-10 C-592A 
(rs1800872)
CC 328 483 1.00 - 1.00 - 1.00 -
AC 149 261 0.84 (0.66-1.07) 0.83 (0.65-1.07) 0.83 (0.64-1.07) 0.14
AA 21 35 0.88 (0.51-1.55) 0.99 (0.56-1.76) 1.00 (0.56-1.77) 0.99
AC and AA 170 296 0.85 (0.67-1.07) 0.85 (0.67-1.08) 0.85 (0.66-1.08) 0.18
IL-10 C-819T 
(rs1800871)
CC 325 483 1.00 - 1.00 - 1.00 -
CT 151 259 0.87 (0.68-1.11) 0.86 (0.67-1.11) 0.85 (0.66-1.10) 0.22
TT 22 37 0.88 (0.51-1.53) 1.00 (0.57-1.74) 1.00 (0.57-1.75) 0.99
CT and TT 173 296 0.87 (0.69-1.10) 0.88 (0.69-1.12) 0.87 (0.68-1.11) 0.27
IL-10 G-1082A 
(rs1800896)
GG 169 238 1.00 - 1.00 - 1.00 -
AG 239 374 0.90 (0.70-1.16) 0.91 (0.70-1.19) 0.93 (0.72-1.22) 0.61
AA 90 167 0.76 (0.55-1.05) 0.78 (0.56-1.08) 0.76 (0.54-1.06) 0.10
AG and AA 329 541 0.86 (0.67-1.09) 0.87 (0.68-1.12) 0.88 (0.68-1.13) 0.31
(rs3024505)
CC 297 522 1.00 - 1.00 - 1.00 -
CT 172 235 1.29 (1.01-1.64) 1.35 (1.05-1.73) 1.34 (1.04-1.73) 0.02
TT 29 22 2.32 (1.31-4.11) 2.37 (1.31-4.29) 2.31 (1.27-4.20) 0.01
CT and TT 201 779 1.37 (1.09-1.74) 1.43 (1.13-1.83) 1.43 (1.12-1.82) 0.004
HO-1 A-413T 
(rs2071746)
AA 162 267 1.00 - 1.00 - 1.00 -
AT 251 373 1.11 (0.86-1.43) 1.10 (0.85-1.42) 1.11 (0.85-1.44) 0.45
TT 85 139 1.01 (0.72-1.41) 1.00 (0.71-1.41) 1.01 (0.71-1.42) 0.98
AT and TT 336 512 1.08 (0.85-1.37) 1.07 (0.84-1.37) 1.08 (0.84-1.38) 0.55
1OR = Odds Ratio, 95%CI = 95% confidence interval,
2 Crude,
3 Adjusted for age and gender,
4 Adjusted for age, gender and smoking status.
5P for the fully adjusted estimate
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homozygous wildtype carriers (results not shown). No
associations between rs3024505 genotype and disease
localisation, or between IL-1β, the three IL-10 promoter
polymorphisms, and HO-1 polymorphisms and age at
diagnosis or disease localisation were found.
Gene-smoking interaction analyses
The effect of smoking habits at diagnosis on the genotype
associations was investigated for CD and UC, respec-
tively (Additional file 1: Interaction between the studied
polymorphisms and smoking status in relation to risk of
Crohns Disease and Additional file 2: Interaction
between the studied polymorphisms and smoking status
in relation to risk of ulcerative colitis). No consistent
interactions between smoking status and any of the geno-
types were found.
Discussion
The present case-control study showed that the
rs3024505 marker polymorphism flanking the IL-10 gene
was significantly associated with risk of CD and UC, and,
furthermore, with risk of a diagnosis of CD and UC at
young age. None of the polymorphisms IL-1β T-31C, IL-
10 G-1082A, C-819T, C-592A, or HO-1 A-413T were
associated with risk of CD, UC, or UC and CD combined.
No consistent interactions between smoking status and
genotypes were found.
Our results replicate the findings by Franke et al. [29]
(Table 4). In addition, we found that the association was
carried by a stronger association in the younger age
group. Franke et al found that the variant allele of
rs3024505 was associated with increased risk of UC with
OR of 1.46 (95% CI: 1.31-1.62) and with CD with OR of
1.17 (95% CI: 1.01-1.34). Furthermore, they found no
association between the three IL-10 promoter polymor-
phisms and risk of UC (results regarding CD were not
reported). Previous studies were unable to find associa-
tion between IBD and the IL-10 promoter polymor-
phisms [22,31,35,39,40] whereas other studies have found
associations between paediatric onset of CD and IL-10 C-
819T wildtype allele [30], Crs2222202T variant allele [30]
and between the IL-10 G-1082A variant allele and risk of
UC [58] (Table 4).
The biological significance of rs3024505 in IBD
remains unclear [29]. The polymorphism is is located in
an intergenic region proximal to the 3'UTR end of the IL-
10 gene. The region has a high potential for containing
regulatory sequences, and may thus regulate IL-10 gene
expression [29]. Furthermore, rs3024505 is in perfect
linkage with other polymorphisms located within the IL-
10 gene [29]. On the other hand, since no associations
were found between risk of UC or CD and the IL-10 pro-
moter polymorphisms with proven functional effects on
the IL-10 gene expression, this may suggest either that the
rs3024505 has a much stronger regulatory effect on IL-10
levels than the promoter polymorphisms or that the
effect of the polymorphism on disease risk is unrelated to
IL-10 expression.
IL-1β, IL-10 and HO-1 are key players in the homeosta-
sis of the intestinal immune system. Due to their pro-
inflammatory and anti-inflammatory effects they are of
significance for the development and maintenance of
chronic inflammation. IL-1β has pro-inflammatory
effects, whereas IL-10 and HO-1 have anti-inflammatory
effects. A substantial number of studies document the
roles of the interleukins, including IL-1β and IL-10, and
HO-1 in intestinal inflammation in various animal IBD
models and in IBD patients [15,25,26,43-47]. Therefore,
genetic variations in these genes may cause imbalance in
intestinal homeostasis and thereby contribute to chronic
Table 4: Odds ratios and 95% confidence intervals (OR (CI)) for associations between IL-10 gene polymorphisms and 
ulcerative colitis (UC) or Crohns disease (CD) in selected case-control studies3.
Ncases/control Trs3024505C1 Grs3024493T1 C-819T2 
(rs1800871)
C-592A2 
(rs1800872)
G-1082A2 
(rs1800896)
Crs2222202T
UC
1855/3091 1.46 (1.31-1.62) Neg Neg neg [29]
203/391 neg 1.66 (1.30-2.14) [36]
CD
1848/1804 1.17 (1.01-1.34) [29]
270/336 neg 0.77 (0.58-1.00) 1.29 (1.01-1.64) [30]
234-6/188-231 neg neg [35]
1rs3024505 and rs3024493 are in complete linkage disequilibrium [30]
2IL-10 G-1082A, C-819T, and C-592A are in linkage disequilibrium [32] C-819T, and C-592A are in complete linkage disequilibrium [34]
3Negative associations are indicated by "Neg"
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Page 8 of 10inflammation. On this background, IL-1β, IL-10 and HO-
1 are relevant candidates for IBD susceptibility genes.
Our results are in accordance with previous studies
which were unable to find association between IBD and
IL-1β T-31C [24], taqI [19,23] or C-511T [20,21]. The
HO-1 A-413T polymorphism has not previously been
studied in relation to IBD, whereas no association was
found between IBD and HO-1 (GT)N [49]. However, all
these studies were small, the largest studies included 500
participants, and thus with limited statistical power to
exclude an association. The polymorphisms analysed in
the present study, IL-1β T-31C, and HO-1 A-413T have
been shown to have biological effect [18,48,59], and the
SNPs have previously been associated to risk of various
disease entities [48,60].
We found no consistent interactions between the stud-
ied polymorphisms and smoking in relation to risk of CD
or UC. Although both smoking and nicotine administra-
tion lower the exaggerated IL-1β response in IBD patients
[61,62], the present study does not indicate that smoking
at the time of diagnosis influences IBD risk by pathways
involving IL-1β, IL-10 or HO-1, since the polymorphisms
had no effect among present smokers. Cigarette smoke
has been reported to act differentially on inflammation in
the small and large intestine, thus worsening small intes-
tinal inflammation, but ameliorating colitis [63]. We were
not able to perform subgroup analyses to target this ques-
tion due to limited statistical power.
It is important to stress the strengths and limitations of
the study. The present study included 1600 participants
and power analyses showed that this study has more than
80% power to detect a dominant effect with an OR of 1.5
in relation to either CD or UC and or 1.4 if CD and UC
were combined. Moreover, genetic determinants may be
stronger among patients with extensive disease and ileal
disease [64,65] and disease onset at low age. The effects
of the polymorphisms might thus be below the detection
level of our study.
Conclusions
In conclusion, the rs3024505 marker polymorphism
flanking the IL-10 gene was associated with risk of UC
and CD in the present Danish case-cohort study, and, fur-
thermore, with risk of a diagnosis of CD and UC at young
age. None of the polymorphisms IL-1β T-31C, IL-10 G-
1082A, C-819T, C-592A, or HO-1 A-413T were associ-
ated with risk of CD or UC. No consistent interactions
between smoking status and genotypes were found. The
study suggests that IL-10, but not IL-1β or HO-1, play a
role in IBD etiology.
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